Lantus biosimilar developed by Merck, Samsung Bioepis under U.S. FDA review
IndustryAug 9, 2016
The U.S. Food and Drug Administration has accepted for review a new Lantus biosimilar developed by U.S.-based Merck Sharp & Dohme with partial funding from Samsung Bioepis, MSD said last Friday.MSD’s biosimilar drug MK-1293 references Lantus, an insulin-based diabetes treatment originally developed by Sanofi. Samsung Bioepis has contributed to MK-1293’s development as an investment partner to MSD.A Samsung Bioepis employee (Samsung Bioepis)MK-1293 is already undergoing a marketing authorization